Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SRZN vs IBO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Captures Overall Composite Edge (32.8 SELL vs 36.8 SELL), While IBO Leads 3–2 on Growth & Valuation Pillars

SRZN Overall Winner 6-Pillar Tally: SRZN 2 – 3 IBO (1 Tie) Matrix Metrics: SRZN 5 – 4 IBO

As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Impact BioMedical, Inc. (IBO) on higher Unified Composite conviction (32.8/100 SELL vs. 36.8/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while IBO wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $32.32 (N/M Forward P/E, -485.4% operating margin) versus IBO at $4.91 (N/M Forward P/E, -12621.0% operating margin).

  • Composite vs. Pillar Nuance: While IBO currently prints a higher short-term Unified Composite Score (36.8/100 SELL vs. SRZN 32.8/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -12621.0% operating margin) and revenue trajectory (+408.6% vs. +16.7% YoY).
  • Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both SRZN (32.8/100 SELL) and IBO (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs IBO
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$32.32
+2.25% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.21β · 62% Vol
Unified Composite Score
32.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.1% over 20 days), RSI 63
RSI-14: 62.9 · SMA20: $29.54 · SMA50: $26.11
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
TTM Revenue $2.6M
Forward P/E N/M
Beta / 30D Vol -6.72β · 120% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (71.0% over 20 days), RSI 62
RSI-14: 62.4 · SMA20: $4.12 · SMA50: $3.52

6-Pillar Scorecard Institutional Category Breakdown (SRZN 2 – 3 IBO)

Columns: Metric · SRZN · IBO
1. Valuation Multiples IBO
Forward P/E N/M N/M
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue 48.3x 17.4x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% +16.7%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $2.6M
Market Cap $602.5M $44.4M
3. Profitability & Quality IBO
Gross Margin N/A N/A
Operating Margin -485.4% -12621.0%
Net Profit Margin 0.0% 4247.4%
Return on Equity (ROE) -62.8% 71.2%
4. Balance Sheet & Cash Flow IBO
Cash Generation (TTM) -$31M -$284M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $1.18 Book/Sh · 71.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (5th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (5) vs IBO (4)
Institutional Metric SRZN IBO Criterion Row Edge
Market Capitalization
Scale
$602.5M $44.4M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple IBO
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% +16.7% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% -12621.0% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 4247.4% Higher Margin IBO
Return on Equity (ROE)
Capital Efficiency
-62.8% 71.2% Higher ROE IBO
52-Week Range Position
Momentum
79% ($12–$38) 67% ($0–$7) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.21β · 62% Vol -6.72β · 120% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
32.8 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite IBO
Trailing 12M Revenue (USD)
Operating Scale
$11M $2.6M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.3x EV/Rev N/M PEG · 17.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$284M EBITDA ($1.18 Book/Sh · 71.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBO +45.33 pp
SRZN: +37.88% · IBO: +83.21%
3M Horizon IBO +910.01 pp
SRZN: +34.67% · IBO: +944.68%
6M Horizon IBO +794.35 pp
SRZN: +17.78% · IBO: +812.13%
1Y Horizon IBO +696.08 pp
SRZN: +166.67% · IBO: +862.75%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue IBO Revenue SRZN Op. Margin IBO Op. Margin Margin Leader
FY2022 $10M $0M -354.7% -6808.0% SRZN
FY2024 $10M N/A -239.7% N/A SRZN
FY2025 $0M $0M -1210.6% -13381.2% SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
37d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
IBO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $44.4M market capitalization and -12621.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs IBO Key Questions & Quantitative Answers

As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) captures the overall head-to-head institutional edge over Impact BioMedical, Inc. (IBO) on higher Unified Composite conviction (32.8/100 SELL vs. 36.8/100 SELL) after splitting the core matrix 5–4 (led by Growth & Scale, Options & Positioning), while IBO wins 3–2 across the 6-pillar growth and valuation breakdown. SRZN trades at $32.32 (N/M Forward P/E, -485.4% operating margin) versus IBO at $4.91 (N/M Forward P/E, -12621.0% operating margin). Composite vs. Pillar Nuance: While IBO currently prints a higher short-term Unified Composite Score (36.8/100 SELL vs. SRZN 32.8/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -12621.0% operating margin) and revenue trajectory (+408.6% vs. +16.7% YoY). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both SRZN (32.8/100 SELL) and IBO (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with IBO at +16.7% YoY revenue growth and +0.0% YoY earnings growth on $2.6M TTM revenue (N/A gross margin, -12621.0% operating margin). Across the 3-period historical trajectory (FY2022 to FY2025), SRZN cumulative revenue shifted +0.0% while IBO shifted N/A. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IBO.

IBO screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas IBO trades at N/M Forward P/E, 0.4x Trailing P/E, N/M PEG, and 17.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus IBO (71.2% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk). By comparison, IBO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-6.72β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.